Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tribromoethanol SCHEMBL26851 | 1.00 | — | — | |
| Tribromoethanol SCHEMBL10344981 | 0.83 | ALDH1A1 (0.36) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Tribromoethanol SCHEMBL11210485 | 0.80 | LMNA (0.43) | ALDH1A1TSHRLMNA | |
| Amylene Hydrate SCHEMBL6118867 | 0.75 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL10478797 | 0.74 | — | — | |
| SCHEMBL8322270 | 0.74 | ALDH1A1 (0.38) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| SCHEMBL2761146 | 0.74 | — | — | |
| SCHEMBL244845 | 0.70 | — | — | |
| SCHEMBL11856250 | 0.70 | — | — | |
| SCHEMBL9699801 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11690888-B2 | Composition for preventing or treating menopausal syndrome, containing medicinal herb extract as active ingredient | DONGGUK UNIVERSITY WISE CAMPUS INDUSTRY-ACADEMY COOPERATION FOUNDATION (KR) | 2023-07-04 | — | — | US | disclosed |
| US-20200138889-A1 | COMPOSITION FOR PREVENTING OR TREATING MENOPAUSAL SYNDROME, CONTAINING MEDICINAL HERB EXTRACT AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY GYEONGJU INDUSTRY-ACADEMY COOPERATION FOUNDATION (KR) | 2020-05-07 | — | — | US | disclosed |
| US-8664176-B2 | Treatment for age-related macular degeneration and other diseases of the eye | CELLDEX THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2083841-B1 | SOLUBLE COMPLEMENT RECEPTOR TYPE I (sCR1) PROTEIN FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES OF THE EYE | CELLDEX THERAPEUTICS INC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20100130413-A1 | TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES OF THE EYE | CELLDEX THERAPEUTICS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2083841-A2 | TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES OF THE EYE | Celldex Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008048675-A2 | TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES OF THE EYE | CELLDEX THERAPEUTICS, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130413-A1 | TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES OF THE EYE | AGER, RBP1, CFH | ALDH1A1 765/4885TSHR 450/4885LMNA 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.